A deadly strain of malaria along the Thai-Cambodian border is becoming increasingly immune to treatment, threatening the global effort to end malaria, new evidence shows. Artemisinin combination therapy (ACT), whereby patients take both a fast-acting and slow-acting drug to kill the parasite, is losing its therapeutic effects as treatment is taking longer. The parasite's resistance to Artemisinin, one of two drugs in ACT therapy, is the driving factor behind the deterioration of ACT. (IRIN)

About the author

  • Devex Editor

    Thanks a lot for your interest in Devex News. To share news and views, story ideas and press releases, please email We look forward to hearing from you.